Sartorius AG

euro adhoc: Sartorius AG
Financial Figures/Balance Sheet
Preliminary Figures for Fiscal 2005

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@


Group earnings (EBIT) improved by 34.3% / Earnings per share up  from EUR0.89 to EUR1.30 / Sales revenue up 3.6% / Order intake up 7.7% / Profitable growth expected to be continued in 2006

In fiscal 2005, the Sartorius Group boosted earnings before interest, taxes, depreciation and amortization (EBITDA) 14.1% from EUR54.8 million to EUR62.5 million. Earnings before interest and taxes (EBIT) reached EUR43.7 million and were thus 34.3% above the year-earlier figure (EUR32.5 mn). This corresponds to an EBIT margin of 9.0% (previous year: 7.0%). For the Biotechnology Division, EBIT was EUR24.3 million (EUR17.5 mn); for the Mechatronics Division, EUR19.4 million (EUR15.0 mn).

As goodwill amortization ceased to be applied (EUR2.4 mn), this had a positive impact on EBIT. Expenses for derivative financial instruments had a negative impact in a similar amount on the financial result. Net profit surged 45.1% to EUR22.1 million (EUR15.2 mn); earnings per share climbed from EUR0.89 to EUR1.30.

Group sales revenue rose 3.6% (currency adjusted: +3.5%) to EUR484.3 million (EUR467.6 mn). The Biotechnology Division posted a 4.3% increase in sales revenue to EUR249.8 million (EUR239.4 mn); the Mechatronics Division, 2.8% to EUR234.5 million (EUR228.1 mn). Consolidated order intake grew 7.7% (currency adjusted: +7.7%) to EUR497.0 million (EUR461.6 mn).

The considerably positive net cash flow of EUR33.0 million (EUR36.3 mn) was primarily used to reduce net debt by EUR18.1 million to EUR60.7 million.

In fiscal 2006, Sartorius is striving to continue profitable growth and, on the basis of constant currencies, assumes that it will achieve an increase in sales revenue of over 5%. In addition, the company intends to raise EBIT to approx. 10% of consolidated sales revenue.

The figures stated above are still subject to the auditors' final review. The final numbers will be published at the annual press conference, which has been moved up to March 14, 2006.

@@start.t2@@end of announcement                                                 euro adhoc 02.02.2006 20:07:37

ots Originaltext: Sartorius AG
Im Internet recherchierbar:

Further inquiry note:
Andreas Wiederhold
Phone +49.551.308.1668

Branche: Biotechnology
ISIN:      DE0007165607
WKN:        716560
Index:    CDAX, Prime All Share, Technologie All Share
Börsen:  Frankfurter Wertpapierbörse / official dealing/prime standard
              Börse Berlin-Bremen / free trade
              Hamburger Wertpapierbörse / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Bayerische Börse / free trade
              Niedersächsische Börse zu Hannover / official dealing

Original-Content von: Sartorius AG, übermittelt durch news aktuell

Weitere Meldungen: Sartorius AG

Das könnte Sie auch interessieren: